KR20170040209A - 경피 크림 - Google Patents

경피 크림 Download PDF

Info

Publication number
KR20170040209A
KR20170040209A KR1020177002451A KR20177002451A KR20170040209A KR 20170040209 A KR20170040209 A KR 20170040209A KR 1020177002451 A KR1020177002451 A KR 1020177002451A KR 20177002451 A KR20177002451 A KR 20177002451A KR 20170040209 A KR20170040209 A KR 20170040209A
Authority
KR
South Korea
Prior art keywords
amount
progesterone
pharmaceutical composition
estradiol
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020177002451A
Other languages
English (en)
Korean (ko)
Inventor
피터 페르시카너
아제이 간타
줄리아 아마디오
제이슨 레가시
토르스테인 토르스테인손
아네트 샤디아크
리차드 윈케르
Original Assignee
쎄러퓨틱스엠디, 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 쎄러퓨틱스엠디, 인코퍼레이티드 filed Critical 쎄러퓨틱스엠디, 인코퍼레이티드
Publication of KR20170040209A publication Critical patent/KR20170040209A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020177002451A 2014-07-29 2015-07-29 경피 크림 Withdrawn KR20170040209A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462030540P 2014-07-29 2014-07-29
US62/030,540 2014-07-29
US201562152674P 2015-04-24 2015-04-24
US62/152,674 2015-04-24
PCT/US2015/042621 WO2016018993A1 (en) 2014-07-29 2015-07-29 Transdermal cream

Publications (1)

Publication Number Publication Date
KR20170040209A true KR20170040209A (ko) 2017-04-12

Family

ID=55178912

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177002451A Withdrawn KR20170040209A (ko) 2014-07-29 2015-07-29 경피 크림

Country Status (11)

Country Link
US (2) US10098894B2 (enExample)
EP (1) EP3174542A4 (enExample)
JP (1) JP2017523138A (enExample)
KR (1) KR20170040209A (enExample)
AU (1) AU2015296609A1 (enExample)
BR (1) BR112016029338A2 (enExample)
CA (1) CA2951284A1 (enExample)
IL (1) IL248984A0 (enExample)
MX (1) MX2016013693A (enExample)
RU (1) RU2016141135A (enExample)
WO (1) WO2016018993A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9814701B2 (en) 2009-12-11 2017-11-14 Aldeyra Therapeutics, Inc. Compositions and methods for the treatment of macular degeneration
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
RS62297B1 (sr) 2011-11-23 2021-09-30 Therapeuticsmd Inc Prirodne kombinovane hormonske supstitucione formulacije i terapije
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CN105120866B (zh) 2013-01-23 2020-02-14 奥尔德拉医疗公司 与毒性醛相关的疾病和治疗
JP2017516768A (ja) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然の併用ホルモン補充療法剤及び療法
US10328087B2 (en) * 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017035077A1 (en) 2015-08-21 2017-03-02 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
WO2017173191A1 (en) * 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
EP3436023A4 (en) * 2016-04-01 2019-10-16 TherapeuticsMD, Inc. Pharmaceutical steroid hormone composition
CN111356451A (zh) 2017-10-10 2020-06-30 奥尔德拉医疗公司 炎性病症的治疗
WO2020028820A1 (en) * 2018-08-03 2020-02-06 Aldeyra Therapeutics, Inc. Topical compositions and methods of preparation and use
US12006298B2 (en) 2018-08-06 2024-06-11 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
CA3137301A1 (en) 2019-05-02 2020-11-05 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
EP4149470A4 (en) 2020-05-13 2024-04-24 Aldeyra Therapeutics, Inc. Pharmaceutical formulations and uses thereof
IT202200005462A1 (it) * 2022-03-21 2023-09-21 Green Innovation Gmbh Veterinary topical composition for the antimicrobic treatment of dairy animal udders / composizione topica veterinaria per il trattamento antimicrobico delle mammelle degli animali da latte

Family Cites Families (324)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB589946A (en) 1945-04-05 1947-07-03 Paul Alphonse Hubert Mossay Improvements connected with controlling means for electric hoisting motors
GB848881A (en) 1955-12-27 1960-09-21 Upjohn Co Improvements in or relating to hormone compositions and the preparation thereof
US3948254A (en) 1971-11-08 1976-04-06 Alza Corporation Novel drug delivery device
US3971367A (en) 1972-12-27 1976-07-27 Alza Corporation Intrauterine device having means for changing from uterine-retentive shape to nonuterine-retentive shape
US3921636A (en) 1973-01-15 1975-11-25 Alza Corp Novel drug delivery device
FR2408345A1 (fr) 1976-11-30 1979-06-08 Besins Jean Louis Nouvelle composition a action anti-conceptionnelle
US4310510A (en) 1976-12-27 1982-01-12 Sherman Kenneth N Self administrable anti-fertility composition
GB1589946A (en) 1977-12-14 1981-05-20 Kali Chemie Pharma Gmbh Enterally absorbable preparations and process for the production thereof
US4372951A (en) 1979-10-11 1983-02-08 Nichols Vorys Vaginal delivery for physiologic follicular-luteal steroid treatment
US5140021A (en) 1986-04-16 1992-08-18 Genesis Systems Corporation Method and dosage form for treatment of premenstrual syndrome
US6139868A (en) 1986-08-28 2000-10-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system, its use and production process
US4865848A (en) 1987-02-26 1989-09-12 Alza Corporation Skin permeation enhancer compositions using sucrose esters
US4788062A (en) 1987-02-26 1988-11-29 Alza Corporation Transdermal administration of progesterone, estradiol esters, and mixtures thereof
US4900734A (en) 1987-08-27 1990-02-13 Maxson Wayne S Novel pharmaceutical composition containing estradiol and progesterone for oral administration
US5064654A (en) 1989-01-11 1991-11-12 Ciba-Geigy Corporation Mixed solvent mutually enhanced transdermal therapeutic system
US5474783A (en) 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
JP2651616B2 (ja) * 1989-02-03 1997-09-10 リンテック株式会社 経皮吸収製剤
US5164416A (en) 1989-02-03 1992-11-17 Lintec Corporation Transdermal therapeutic formulation containing a limonene
US4973468A (en) 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
GB9113726D0 (en) 1991-06-25 1991-08-14 Inst Of Animal Physiology And Artificial animal foster mothers
MX9301121A (es) 1992-03-02 1993-09-01 Schering Ag Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina.
US5453279A (en) * 1992-04-21 1995-09-26 Tbs Laboratories, Inc. Enhancing transdermal absorption compositions; transdermal dosage form; and process
US5843979A (en) 1993-02-25 1998-12-01 Bristol-Myers Squibb Company Transdermal treatment with mast cell degranulating agents for drug-induced hypersensitivity
SE9301171D0 (sv) 1993-04-07 1993-04-07 Ab Astra Pharmaceutical composition containing lipophilic drugs
US5595970A (en) 1993-07-16 1997-01-21 Schering Aktiengesellschaft Treatment of climacteric disorders with nitric oxide synthase substrates and/or donors
US5543150A (en) 1993-09-15 1996-08-06 Columbia Laboratories, Inc. Method of progesterone delivery and affect thereof
ATE183926T1 (de) 1993-09-29 1999-09-15 Alza Corp Hautpermeabilitaetserhöher bestehend aus monoglycerid/laktat estern
DE4344463A1 (de) 1993-12-22 1995-06-29 Schering Ag Kombinationsprodukt zur Kontrazeption
GB9405304D0 (en) 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5811416A (en) 1994-06-06 1998-09-22 Board Of Regents The University Of Texas System Endothelin antagonist and/or endothelin synthase inhibitor in combination with a progestin, an estrogen, a cyclooxygenase inhibitor, or a nitric acid donor or substrate
FR2722102B1 (fr) 1994-07-11 1996-08-23 Cird Galderma Utilisation de particules creuses deformables dans une composition cosmetique et/ou dermatologique, contenant des matieres grasses
US5633011A (en) 1994-08-04 1997-05-27 Alza Corporation Progesterone replacement therapy
US6613757B1 (en) 1994-09-22 2003-09-02 Board Of Regents, The University Of Texas System Combination of prostacyclin with an estrogen or progestin for the prevention and treatment of atherosclerotic vascular disease including preeclampsia and for the treatment of hypertension, and for hormone replacement therapy
US5565199A (en) 1995-02-07 1996-10-15 Page; Elliot W. Systems and methods for the synthesis of natural base steroidal hormones and more especially estrogens and progesterone and estrogen-like and progesterone-like compounds and their derivatives derived as phytohormones from herbaceous plants
US5609617A (en) 1995-02-21 1997-03-11 C. Norman Shealy Method for enhancement of dehydroepiandrosterone
FR2732223B1 (fr) 1995-03-30 1997-06-13 Sanofi Sa Composition pharmaceutique pour administration transdermique
US5882676A (en) 1995-05-26 1999-03-16 Alza Corporation Skin permeation enhancer compositions using acyl lactylates
US7833543B2 (en) 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US5780050A (en) 1995-07-20 1998-07-14 Theratech, Inc. Drug delivery compositions for improved stability of steroids
DE19526864A1 (de) 1995-07-22 1997-01-23 Labtec Gmbh Hormonpflaster
US5840327A (en) 1995-08-21 1998-11-24 Alza Corporation Transdermal drug delivery device having enhanced adhesion
US5898038A (en) 1996-03-19 1999-04-27 Board Of Regents, The University Of Texas System Treatment of osteoporosis and metabolic bone disorders with nitric oxide substrate and/or donors
FR2747042B1 (fr) 1996-04-05 1998-06-05 Besins Iscovesco Lab Medicament a base de progesterone et d'oestradiol
IL127189A0 (en) 1996-05-22 1999-09-22 Diversified Pharmaceuticals In Compositions methods and devices for the transdermal delivery of drugs
US5744463A (en) 1996-06-03 1998-04-28 Bair; Glenn O. Treatment of side effects of progestins and progesterone analogues used for birth control
IT1283102B1 (it) * 1996-06-06 1998-04-07 Permatec Nv Composizione terapeutica per la somministrazione transdermica di un principio attivo estrogeno o progestinico o di loro miscele
US6139873A (en) 1996-07-10 2000-10-31 Cedars-Sinai Medical Center Combined pharmaceutical estrogen-androgen-progestin
US6228852B1 (en) 1996-07-12 2001-05-08 Carolyn V. Shaak Transdermal application of naturally occurring steroid hormones
EP0931263A1 (en) 1996-09-06 1999-07-28 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Method of screening for side effects of anticonceptives or estrogen and/or progesterone replacements or supplements
DE69735435T2 (de) 1996-10-18 2006-09-14 Arizona Chemical Co., Jacksonville Ester-terminierte polyamidgele
US5985861A (en) 1996-11-04 1999-11-16 Columbia Laboratories, Inc. Progesterone for treating or reducing ischemia
US5814329A (en) 1996-11-12 1998-09-29 Polytherapeutics, Inc. Hydrophilic polystyrene graft copolymer vehicle for intravaginal administration of pharmacologically active agents
FR2759292B1 (fr) 1997-02-10 2000-08-11 Cird Galderma Utilisation de retinoides en tant qu'agents induisant la pigmentation
US6056972A (en) 1997-02-26 2000-05-02 Dimera, Llc Method for reducing coronary artery reactivity
IT1291362B1 (it) 1997-05-13 1999-01-07 Vectorpharma Int Composizioni farmaceutiche multicomponente bifasiche contenenti sostanze atte a modificare la partizione dei principi attivi
US20040234606A1 (en) 1997-09-12 2004-11-25 Levine Howard L. Localized vaginal delivery without detrimental blood levels
US5968919A (en) 1997-10-16 1999-10-19 Macrochem Corporation Hormone replacement therapy drug formulations for topical application to the skin
US6306914B1 (en) 1997-10-21 2001-10-23 Columbia Laboratories, Inc. Progestin therapy for maintaining amenorrhea
US6193991B1 (en) 1997-10-29 2001-02-27 Atul J. Shukla Biodegradable delivery systems of biologically active substances
WO1999022680A1 (en) 1997-11-03 1999-05-14 Deschutes Medical Products, Inc. Pessary with medicated cartridge
US6030948A (en) 1997-12-19 2000-02-29 Mann; Morris A. Hair regeneration compositions for treatment of alopecia and methods of application related thereto
FR2772617B1 (fr) 1997-12-19 2001-03-09 Besins Iscovesco Lab Comprime de progesterone et son procede de preparation
AU1728099A (en) 1997-12-22 1999-07-12 Alza Corporation Monoglyceride and ethyl palmitate permeation enhancer compositions
IT1298575B1 (it) 1998-02-06 2000-01-12 Vectorpharma Int Composizioni farmaceutiche in forma di nanoparticelle comprendenti sostanze lipidiche e sostanze antifiliche e relativo processo di
FR2775599B1 (fr) 1998-03-09 2001-08-17 Besins Iscovesco Lab Composition pharmaceutique a base de progesterone naturelle de synthese et d'oestradiol et son procede de preparation
FR2776191B1 (fr) 1998-03-23 2002-05-31 Theramex Composition hormonale topique a effet systemique
FR2777784B1 (fr) 1998-04-27 2004-03-19 Arepa Composition pharmaceutique a base d'estrogene et de progesterone
US6277418B1 (en) 1998-06-02 2001-08-21 Baylor College Of Medicine Corn extract contraceptive
FR2779438B1 (fr) 1998-06-03 2004-12-24 Jean Marc Aiache Gel stable, son procede de preparation, et compositions pharmaceutiques le comprenant
WO1999062497A1 (en) 1998-06-03 1999-12-09 Aiache Jean Marc Stable gel mixture in the form of a mixture of oleogel and aqueous gel
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
DE19827732A1 (de) 1998-06-22 1999-12-23 Rottapharm Bv Transdermales System vom Matrix-Typ zur Abgabe von Wirkstoffen mit einer hohen Abgaberate von Steroid-Hormonen und die Verwendung eines derartigen Systems zur Hormonersatztherapie
EP1094781B1 (en) 1998-07-07 2008-07-02 Transdermal Technologies Inc. Compositions for rapid and non-irritating transdermal delivery of pharmaceutically active agents and methods for formulating such compositions and delivery thereof
US6124362A (en) 1998-07-17 2000-09-26 The Procter & Gamble Company Method for regulating hair growth
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US20030104048A1 (en) 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030236236A1 (en) 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6303132B1 (en) 1999-07-16 2001-10-16 Ardell H. Nelson Administering progesterone using EMU oil
JP2003532629A (ja) 1999-09-08 2003-11-05 ワトソン ファーマシューティカルズ， インコーポレイテッド 第４アンモニウム塩の経皮薬剤放出への使用
US6610674B1 (en) 1999-09-28 2003-08-26 University Of Pennsylvania Method of treating inflammatory conditions with progesterone analogs
US6479545B1 (en) 1999-09-30 2002-11-12 Drugtech Corporation Formulation for menopausal women
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US20030180352A1 (en) 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7384650B2 (en) 1999-11-24 2008-06-10 Agile Therapeutics, Inc. Skin permeation enhancement composition for transdermal hormone delivery system
US6708822B1 (en) 1999-11-30 2004-03-23 Cutispharma, Inc. Compositions and kits for compounding pharmaceuticals
US6562370B2 (en) 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of steroid drugs using hydroxide-releasing agents as permeation enhancers
US6544553B1 (en) 1999-12-28 2003-04-08 Watson Pharmaceuticals, Inc. Dosage forms and methods for oral delivery of progesterone
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
AU2991301A (en) 2000-01-28 2001-08-07 Endorecherche Inc. Selective estrogen receptor modulators in combination with estrogens
US6562790B2 (en) 2000-02-05 2003-05-13 Chein Edmund Y M Hormone therapy methods and hormone products for abating coronary artery blockage
AU3982601A (en) 2000-02-23 2001-09-03 Orentreich Foundation For The Methods and compositions for the treatment of alopecia and other disorders of the pilosebaceous apparatus
KR20030019333A (ko) * 2000-03-27 2003-03-06 쇼트 그라스 신규 화장품, 퍼스널 케어, 클리닝제, 및 생체활성 유리를포함하는 영양 보충 조성물 및 이의 제조방법과 용법
GB0015617D0 (en) 2000-06-26 2000-08-16 Vectura Ltd Improved preparations for dermal delivery of active substances
US6420352B1 (en) 2000-07-19 2002-07-16 W. Roy Knowles Hair loss prevention
DE60109295T2 (de) 2000-07-24 2006-04-13 Sugen, Inc., South San Francisco Selbstemulgierendes system zur abgabe von sehr wasserunlöslichen und lipophilen arzneimitteln
US20020035070A1 (en) 2000-07-26 2002-03-21 The Procter & Gamble Company Method of regulating hair growth using metal complexes of oxidized carbohydrates
US20020119174A1 (en) 2000-07-26 2002-08-29 Gardlik John Michael Compositions useful for regulating hair growth containing metal complexes of oxidized carbohydrates
ATE485837T1 (de) 2000-08-03 2010-11-15 Antares Pharma Ipl Ag Zusammensetzung zur transdermalen und/oder transmukosalen verabreichung von wirkstoffen, die ausreichende therapeutische spiegel garantiert
FR2814074B1 (fr) 2000-09-15 2003-03-07 Theramex Nouvelles compositions estro-progestatives topiques a effet systemique
CZ2003808A3 (cs) 2000-09-20 2003-08-13 Nycomed Pharma As Způsob výroby prostředku ve formě kapalné emulse
US6635274B1 (en) 2000-10-27 2003-10-21 Biochemics, Inc. Solution-based transdermal drug delivery system
US6682757B1 (en) 2000-11-16 2004-01-27 Euro-Celtique, S.A. Titratable dosage transdermal delivery system
IL155703A0 (en) 2000-11-17 2003-11-23 Warner Lambert Co Treatment of sexual dysfunction with non peptide bombesin receptor antagonists
US6743448B2 (en) 2000-12-11 2004-06-01 Abraham H. Kryger Topical testosterone formulations and associated methods
FR2818905A1 (fr) 2000-12-28 2002-07-05 Cll Pharma Compositions pharmaceutiques colloidales micellaires renfermant un principe actif lipophile
US7381427B2 (en) 2001-02-09 2008-06-03 Mickey Miller Seborrheic keratosis treatment
FR2821555B1 (fr) 2001-03-01 2003-05-16 Besins Int Lab Progestatif co-micronise avec un tensioactif, composition pharmaceutique le comprenant, leurs procedes de fabrication et leurs utilisations
FR2828102B1 (fr) 2001-03-28 2004-07-09 Ifc Sa Utilisation des lipoaminoacides dans une composition pharmaceutique comme promoteur et systeme disperse a usage pharmaceutique contenant de tels composes
US20040131670A1 (en) 2001-04-17 2004-07-08 Ping Gao Pellicle-resistant gelatin capsule
US20070021360A1 (en) 2001-04-24 2007-01-25 Nyce Jonathan W Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase
US20120322779A9 (en) 2001-04-25 2012-12-20 Rhonda Voskuhl Estriol Therapy for Autoimmune and Neurodegenerative Diseases and Disorders
US20050209208A1 (en) 2001-04-25 2005-09-22 The Regents Of The University Of California Use of estriol and other estranes, estrogens and estrogen receptor active compositions in the treatment of psoriasis and other autoimmune disorders
US7094228B2 (en) 2001-07-31 2006-08-22 Zars, Inc. Methods and formulations for photodynamic therapy
DK1455888T3 (da) 2001-08-29 2009-08-24 Pharmakodex Ltd Topisk indgivelsesindretning
AU2002340120A1 (en) 2001-10-04 2003-04-14 Cellegy Pharmaceuticals, Inc. Semisolid topical hormonal compositions and methods for treatment
FR2832065B1 (fr) 2001-11-13 2004-11-05 Besins Int Belgique Composition pharmaceutique a base de progesterone micronisee son procede de preparation et ses utilisations
DE10159120B4 (de) 2001-12-01 2006-08-17 Lts Lohmann Therapie-Systeme Ag Steroidhormonhaltige transdermale therapeutische Systeme enthaltend Propylenglycolmonocaprylat und seine Verwendung
AU2002353118A1 (en) 2001-12-11 2003-07-24 Dor Biopharma, Inc. Lipid particles and suspensions and uses thereof
ES2188426B1 (es) 2001-12-12 2004-11-16 Rosalia Pidal Fernandez Composicion farmaceutica para el tratamiento de la psoriasis y otras dermopatias.
AU2002364212B2 (en) 2001-12-21 2007-09-20 Shire Laboratories Inc. Oral capsule formulation with increased physical stability
AU2003208679A1 (en) 2002-02-08 2003-09-02 Advanced Animal Technology Limited Control of a biological function
CN1622810A (zh) 2002-03-14 2005-06-01 华生制药公司 孕酮口服药物传输系统
IL164163A0 (en) 2002-04-09 2005-12-18 Pharmacia Corp Process for preparing a finely self-emulsifiable pharmaceutical composition
JP2005525401A (ja) 2002-04-23 2005-08-25 ニュートリション ２１、インコーポレイテッド 薬剤誘発インスリン抵抗性を阻害するためのクロム組成物およびその使用方法
US20050131005A1 (en) 2002-04-30 2005-06-16 Jiabing Wang 4-azasteroid derivatives as androgen receptor modulators
KR100533458B1 (ko) 2002-07-20 2005-12-07 대화제약 주식회사 파클리탁셀의 가용화용 조성물 및 그의 제조 방법
AU2002950713A0 (en) 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
US6967194B1 (en) 2002-09-18 2005-11-22 Susan Matsuo Bio-identical hormones and method of use
US20070292461A1 (en) 2003-08-04 2007-12-20 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US20070292359A1 (en) 2002-10-25 2007-12-20 Foamix Ltd. Polypropylene glycol foamable vehicle and pharmaceutical compositions thereof
US20060247216A1 (en) 2002-10-25 2006-11-02 Haj-Yehia Abdullah I Steroid compounds comprising superoxide dismutase mimic groups and nitric oxide donor groups, and their use in the preparation of medicaments
US20080206161A1 (en) 2002-10-25 2008-08-28 Dov Tamarkin Quiescent foamable compositions, steroids, kits and uses thereof
DE10249853A1 (de) 2002-10-25 2004-05-13 Liedtke, Rainer K., Dr. Pflasterartige Chip-Systeme zur thermodynamischen Kontrolle topisch dermaler und transdermaler Systeme
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US20040138103A1 (en) 2002-11-07 2004-07-15 Procyte Corporation Compositions containing peptide copper complexes and metalloproteinase inhibitors and methods related thereto
US20040115287A1 (en) 2002-12-17 2004-06-17 Lipocine, Inc. Hydrophobic active agent compositions and methods
US20050031651A1 (en) 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
FR2849380A1 (fr) 2002-12-27 2004-07-02 Ernest Loumaye NOUVELLE UTILISATION D'UN AGONISTE DU GnRH
US7572780B2 (en) 2003-01-21 2009-08-11 Dimera, Incorporated Method and kit for reducing the symptoms of peripheral vascular disease
US7858607B2 (en) 2003-03-14 2010-12-28 Mamchur Stephen A System for use by compounding pharmacists to produce hormone replacement medicine customized for each consumer
US20040191207A1 (en) 2003-03-31 2004-09-30 Lipari John M. Alpha-hydroxy acid ester drug delivery compositions and methods of use
ATE461681T1 (de) 2003-04-29 2010-04-15 Gen Hospital Corp Verfahren und vorrichtungen für die verzögerte freisetzung von mehreren arzneimitteln
US20040253319A1 (en) 2003-06-11 2004-12-16 Shrirang Netke Pharmaceutical compositions and method for alleviating side-effects of estrogen replacement therapy
PL1844765T3 (pl) 2003-06-13 2015-06-30 Skendi Finance Ltd Formulacja estradiol-progesteron o spowolnionym uwalnianiu
US20040259852A1 (en) 2003-06-18 2004-12-23 White Hillary D. Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome
US20110318405A1 (en) 2003-06-25 2011-12-29 Charles Erwin Chemical Combination and Method for Increasing Delivery of Coenzyme Q10
ES2237298B1 (es) 2003-07-16 2006-11-01 Italfarmaco, S.A. Formulaciones mucoadhesivas semisolidas.
US20050020552A1 (en) 2003-07-16 2005-01-27 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US20080069779A1 (en) 2003-08-04 2008-03-20 Foamix Ltd. Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof
EP2617411A1 (en) 2003-09-03 2013-07-24 Miscon Trading S.A. Methods for the Treatment of Endometriosis
HUP0303313A2 (hu) 2003-10-09 2005-07-28 Richter Gedeon Vegyészeti Gyár Rt. Transzdermális gyógyszerkészítmények
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
US20050101579A1 (en) 2003-11-06 2005-05-12 Shippen Eugene R. Endometriosis treatment protocol
ES2258694T3 (es) 2003-11-11 2006-09-01 Mattern, Udo Sistema de administracion de liberacion controlada de hormonas sexuales para aplicaciones nasales.
US20050186183A1 (en) 2003-12-08 2005-08-25 Deangelo Joseph Stabilized products, processes and devices for preparing same
IL159729A0 (en) 2004-01-06 2004-06-20 Doron I Friedman Non-aqueous composition for oral delivery of insoluble bioactive agents
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US20050182105A1 (en) 2004-02-04 2005-08-18 Nirschl Alexandra A. Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function
ES2325591T3 (es) 2004-03-10 2009-09-09 Bayer Schering Pharma Aktiengesellschaft Composiciones que comprenden drospirenona dispersada molecularmente.
US20050220825A1 (en) 2004-03-10 2005-10-06 Adrian Funke Molecular dispersions of drospirenone
MY142989A (en) 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
US20050239747A1 (en) 2004-04-21 2005-10-27 Pharmaceutical Industry Technology And Development Center Compositions and methods of enhanced transdermal delivery of steroid compounds and preparation methods
US20050239758A1 (en) 2004-04-21 2005-10-27 Roby Russell R Hormone treatment of multiple sclerosis
US20050244522A1 (en) 2004-04-30 2005-11-03 Carrara Dario Norberto R Permeation enhancer comprising genus Curcuma or germacrone for transdermal and topical administration of active agents
US20050250746A1 (en) 2004-05-06 2005-11-10 Matthew Iammatteo Premenstrual dysphoric disorder medication
FR2870125B1 (fr) 2004-05-12 2010-03-26 Dermaconcept Jmc Formulation du type spot-on utile en cosmetologie et en dermatologie
US20070196453A1 (en) 2004-06-07 2007-08-23 Jie Zhang Two or more non-volatile solvent-containing compositions and methods for dermal delivery of drugs
US7879830B2 (en) 2004-09-02 2011-02-01 Wiley Teresa S Hormone replacement composition and method
US20070167418A1 (en) 2004-09-07 2007-07-19 Ferguson Steven W Progesterone/testosterone cream for erectile dysfunction
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
US20060058238A1 (en) 2004-09-15 2006-03-16 Lee Laurent-Applegate Fetal skin cell protein compositions for the treatment of skin conditions, disorders or diseases and methods of making and using the same
WO2006036899A2 (en) 2004-09-27 2006-04-06 Corium International, Inc. Transdermal systems for the delivery of estrogens and progestins
US20060110415A1 (en) 2004-11-22 2006-05-25 Bioderm Research Topical Delivery System for Cosmetic and Pharmaceutical Agents
US20060134188A1 (en) 2004-12-20 2006-06-22 Hans-Peter Podhaisky Transdermal pharmaceutical preparation with a progesterone A-specific ligand (PRASL) as active ingredient
US8703198B2 (en) 2005-03-02 2014-04-22 Aquatrove Biosciences Water-based personal moisturizers and lubricants, in particular vaginal lubricants, and uses thereof
US7473687B2 (en) 2005-03-24 2009-01-06 Emory University Methods for the treatment of a traumatic central nervous system injury
US8241664B2 (en) 2005-04-15 2012-08-14 Clarus Therapeutics, Inc Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
US20060252049A1 (en) 2005-05-04 2006-11-09 Shuler Richard O Growth-promoting and immunizing subcutaneous implant
US8663681B2 (en) 2005-05-26 2014-03-04 Teva Women's Health, Inc. Oral dosage forms comprising progesterone and methods of making and using the same
US8435944B2 (en) 2005-06-03 2013-05-07 Acrux Dds Pty Ltd. Method and composition for transdermal drug delivery
ITBO20050388A1 (it) 2005-06-06 2006-12-07 Alfa Wassermann Spa Formulazione mucoadesive utili in dispositivi medici in preparazioni farmaceutiche
US20060280795A1 (en) 2005-06-08 2006-12-14 Dexcel Pharma Technologies, Ltd. Specific time-delayed burst profile delivery system
US10137135B2 (en) 2005-08-15 2018-11-27 Allergan Sales, Llc Formulations and methods for providing progestin-only contraception while minimizing adverse side effects associated therewith
US8372806B2 (en) 2005-10-06 2013-02-12 Pantec Biosolutions Ag Transdermal delivery system for treating infertility
IE20050723A1 (en) 2005-10-28 2007-05-30 Patrick T Prendergast Anti-mineralocorticoid therapy of infection
GB0524961D0 (en) 2005-12-07 2006-01-18 Pharmakodex Ltd Transdermal administration of active agents for systemic effect
WO2007071448A2 (en) 2005-12-23 2007-06-28 Partnership & Corp. Technology Transfer Synthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of muscle relaxation
CN101365428B (zh) 2006-01-05 2012-08-29 威洛克塞斯药物股份公司 可负载崩解片剂
US20070264309A1 (en) 2006-01-20 2007-11-15 Chollet Janet A Method Of Treating Atrophic Vaginitis
WO2007103294A2 (en) 2006-03-07 2007-09-13 Novavax, Inc. Nanoemulsions of poorly soluble pharmaceutical active ingredients and methods of making the same
JP2009533341A (ja) 2006-04-07 2009-09-17 ノババックス，インコーポレイテッド 抗細菌、抗真菌、抗酵母、および／または抗ウイルス特性を有するナノ構造組成物
WO2007120868A2 (en) 2006-04-14 2007-10-25 Stanley Kepka Bioavailability enhancement of lipophilic drug by use solvent system
US20080039405A1 (en) 2006-04-25 2008-02-14 Croda, Inc. Modification of percutaneous absorption of topically active materials
JP5193196B2 (ja) 2006-06-02 2013-05-08 ペア ツリー ウーマンズ ヘルス ケア 萎縮性膣炎の治療の方法
US20080095831A1 (en) 2006-08-10 2008-04-24 Mc Graw Thomas L Topical formulation of multilamellar vesicles composition for percutaneous absorption of pharmaceutically active agent
EA200970260A1 (ru) 2006-09-08 2009-08-28 Фоамикс Лтд. Окрашенная или окрашиваемая и вспениваемая композиция и пена
RU2480208C2 (ru) 2006-10-04 2013-04-27 М Унд П Патент Акциенгезелльшафт Система доставки с контролируемым высвобождением для назального применения нейротрансмиттеров
CN101646419A (zh) 2006-11-08 2010-02-10 诺瓦瓦克斯股份有限公司 制备多相药物组合物的固体剂型的方法
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
AU2007325207A1 (en) 2006-11-29 2008-06-05 Wyeth Estrogen/ serm and estrogen/ progestin bi-layer tablets
AU2007355106A1 (en) 2006-11-29 2008-12-18 Foamix Ltd. Foamable waterless compositions with modulating agents
US20080132475A1 (en) 2006-12-05 2008-06-05 Charles Gerald Connor Treatment for dry eye
US9918934B2 (en) 2006-12-12 2018-03-20 Edgar Joel Acosta-Zara Linker-based lecithin microemulsion delivery vehicles
WO2008079898A1 (en) 2006-12-20 2008-07-03 Pharmwest, Inc. Methods and topical formulations comprising colloidal metal for treating or preventing skin conditions
GB2445539A (en) 2006-12-29 2008-07-16 Ardana Bioscience Ltd Bigel composition
WO2008089087A2 (en) 2007-01-12 2008-07-24 Wyeth Tablet-in-tablet compositions
EP2051702A1 (en) 2007-01-22 2009-04-29 Novavax, Inc. Multi-phasic pharmaceutical formulations of poorly water-soluble drugs for reduced fed/fasted variability and improved oral bioavailability
US8828981B2 (en) 2007-02-06 2014-09-09 George Creasy Progesterone for the treatment or prevention of spontaneous preterm birth
IL181217A0 (en) 2007-02-08 2007-07-04 Haim Levy Pharmaceuticalcompositions based on a microemulsion
CA2823407C (en) 2007-03-22 2016-10-18 Berg Pharma Llc Topical formulations having enhanced bioavailability
US20090017120A1 (en) 2007-03-23 2009-01-15 Humco Holding Group, Inc. Phase stable lecithin organogel composition
US8569274B2 (en) 2007-04-20 2013-10-29 Preglem S.A. Progesterone antagonist and selective progesterone modulator in the treatment of excessive uterine bleeding
WO2008140794A1 (en) 2007-05-11 2008-11-20 The Texas A & M University System Hormone normalization therapy and uses thereof
US20080312197A1 (en) 2007-06-14 2008-12-18 Rodriguez Gustavo C Pharmaceutical products containing hormones and a 25-hydroxy vitamin d compound
ATE537833T1 (de) 2007-06-21 2012-01-15 Pantarhei Bioscience Bv Behandlung des mekoniumaspirationssyndroms mit östrogenen
WO2009002542A1 (en) 2007-06-27 2008-12-31 Samos Pharmaceuticals, Llc Multi-day delivery of biologically active substances
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
US20100204326A1 (en) 2007-09-06 2010-08-12 Regain Biotechnology Pvt Ltd Novel agents for treatment of ailments and dysfunctions
AR068409A1 (es) 2007-09-14 2009-11-18 Drugtech Corp Composiciones farmaceuticas, transdermicas sin alcohol
EP2191833B1 (en) 2007-09-20 2013-02-13 Shiseido Company, Ltd. Transdermally absorbable preparation
PL2200588T3 (pl) 2007-09-25 2019-09-30 Solubest Ltd. Kompozycje zawierające lipofilowe związki aktywne i sposób ich wytwarzania
BRPI0819081A8 (pt) 2007-10-08 2016-08-30 Fovea Pharmaceuticals Sa Formulação oftálmica aquosa, processo para preparar a mesma, e, método para inibir, tratar ou prevenir doenças oculares e doença ou condição relacionada, em um paciente em necessidade de tal tratamento
US20090130029A1 (en) 2007-11-21 2009-05-21 Foamix Ltd. Glycerol ethers vehicle and pharmaceutical compositions thereof
CA2744906A1 (en) 2007-11-29 2009-06-04 Gregg A. Jackson Progesterone-containing compositions and devices
US8518376B2 (en) 2007-12-07 2013-08-27 Foamix Ltd. Oil-based foamable carriers and formulations
CA2712120A1 (en) 2008-01-14 2009-07-23 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
GB0802403D0 (en) 2008-02-08 2008-03-12 Probiox Sa Compositions for the treatment of oxidative stress
CN102056611A (zh) 2008-04-14 2011-05-11 Posi维森纳里解决方案有限责任公司 用于获得不同的治疗适应症所需要的血浆孕酮水平的方法和药物组合物
ES2327201B1 (es) 2008-04-23 2010-07-23 Ignacio Umbert Millet Composicion farmaceutica personalizada para el rejuvenecimiento de la piel que contiene acido retinoico.
GB0807605D0 (en) 2008-04-28 2008-06-04 Diurnal Ltd Lipid composition
TWI477276B (zh) 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
US20090285869A1 (en) 2008-05-14 2009-11-19 Humco Holding Group, Inc. Salt stable lecithin organogel composition
US20100028360A1 (en) 2008-07-26 2010-02-04 Craig Stephen Atwood Methods for the modulation of brain progestagen signaling in the prevention and treatment of neurological disorders and neurodegenerative diseases
TW201008569A (en) 2008-08-08 2010-03-01 Bayer Schering Pharma Ag Progestin-containing drug delivery system
EP2331707A4 (en) 2008-08-28 2012-06-06 Dermtech Int DETERMINATION OF THE AGING RANGE OF SKIN SAMPLE
EP2218447B1 (en) 2008-11-04 2017-04-19 PharmaSol GmbH Compositions containing lipid micro- or nanoparticles for the enhancement of the dermal action of solid particles
MX2011004994A (es) 2008-11-14 2011-09-28 Y Sk Chemicals Co Ltd Ewha University Industry Collaboration Foundation Metodo para preparar microesferas y microesferas producidas por el mismo.
CN102223799A (zh) 2008-12-06 2011-10-19 细胞内治疗公司 有机化合物
KR20110098731A (ko) 2008-12-06 2011-09-01 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
WO2010065147A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
EP2367429B1 (en) 2008-12-06 2017-06-07 Intra-Cellular Therapies, Inc. Organic compounds
CN102232077A (zh) 2008-12-06 2011-11-02 细胞内治疗公司 有机化合物
EP2358204B1 (en) 2008-12-06 2015-08-05 Intra-Cellular Therapies, Inc. 4,5,7,8-tetrahydro-4-oxo-2H-imidazo[1,2-a]pyrrolo[3,4-e]pyrimidine compounds as PDE1 inhibitors.
EP2379059A4 (en) 2008-12-10 2012-10-31 Anhui Zhongren Technology Co Ltd COMPOSITION WITH CONTROLLED RELEASE
EP2378872A4 (en) 2008-12-18 2012-05-16 B Eugene Guthery TREATMENT PLAN FOR ACNE VULGARIS
CN102438645A (zh) 2009-01-13 2012-05-02 卢布里斯有限责任公司 阴道上皮界面润滑的治疗调节
US20110306579A1 (en) 2009-01-30 2011-12-15 Emory University Methods of neuroprotection using neuroprotective steroids and a vitamin d
WO2010111397A1 (en) 2009-03-24 2010-09-30 Adds Pharmaceuticals Llc Stabilized solubility-enhanced formulations for oral delivery
EP2410859A4 (en) 2009-03-27 2013-03-13 Agile Therapeutics Inc TRANSDERMAL ADMINISTRATION
WO2010117873A2 (en) 2009-04-06 2010-10-14 Banner Pharmacaps, Inc. Progesterone solutions for increased bioavailability
EP2419138A4 (en) 2009-04-14 2013-08-21 Medortus Uk Ltd GEL COMPOSITIONS FOR THE ADMINISTRATION OF PHARMACEUTICALLY ACTIVE COMPOUNDS
US20100273730A1 (en) 2009-04-27 2010-10-28 Innopharmax, Inc. Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof
GB0908129D0 (en) 2009-05-12 2009-06-24 Innovata Ltd Composition
US8658628B2 (en) 2009-06-18 2014-02-25 Karan Y. Baucom Hormone delivery system and method
FR2947178B1 (fr) 2009-06-29 2012-07-06 Effik Composition pharmaceutique a base de progesterone micronisee et ses utilisations
CN101940790B (zh) 2009-07-01 2012-07-25 润和生物医药科技(汕头)有限公司 一种新型促渗剂组合物及其在透皮给药系统中的应用
US8618083B2 (en) 2009-07-31 2013-12-31 Duquesne University Of The Holy Spirit Combination hormone replacement therapy (HRT) and melatonin to prevent and treat mammary cancer
WO2011039637A2 (en) 2009-10-02 2011-04-07 Foamix Ltd. Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US20110086825A1 (en) 2009-10-13 2011-04-14 Chatroux Sylvia S Therapeutic vaginal emollient
US10080760B2 (en) 2009-10-27 2018-09-25 Besins Healthcare Luxembourg Sarl Transdermal pharmaceutical compositions comprising active agents
WO2011073995A2 (en) 2009-12-14 2011-06-23 Lincoln Pharmaceuticals Limited Liquid vaginal spray of progesterone
IN2012DN04867A (enExample) 2009-12-17 2015-09-25 Population Council Inc
WO2011112747A1 (en) 2010-03-09 2011-09-15 Catholic Healthcare West Methods for inhibiting preterm labor and uterine contractility disorders and preventing cervical ripening
EP2552486B1 (en) 2010-03-30 2020-08-12 Phosphagenics Limited Transdermal delivery patch
TW201138782A (en) 2010-04-26 2011-11-16 Besins Healthcare Lu Sarl Low-oil pharmaceutical emulsion compositions comprising progestogen
JP5879336B2 (ja) 2010-05-31 2016-03-08 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
JP5911854B2 (ja) 2010-05-31 2016-04-27 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
WO2011153135A1 (en) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds
BRPI1002601E2 (pt) 2010-06-01 2020-06-30 Embrapa Pesquisa Agropecuaria composição nanoestruturada de uso veterinário para administração de fármacos
JP2012020991A (ja) 2010-06-16 2012-02-02 Takasago Internatl Corp 経皮吸収促進剤、及びこれを含有する皮膚外用製剤
WO2011159770A2 (en) 2010-06-17 2011-12-22 Momenta Pharmaceuticals, Inc. Methods and compositions for modulating hair growth
US20110312928A1 (en) 2010-06-18 2011-12-22 Lipocine Inc. Progesterone Containing Oral Dosage Forms and Related Methods
US20110312927A1 (en) 2010-06-18 2011-12-22 Satish Kumar Nachaegari Progesterone Containing Oral Dosage Forms and Related Methods
WO2011162802A1 (en) 2010-06-21 2011-12-29 Virun, Inc. Compositions containing non-polar compounds
BRPI1002486B1 (pt) 2010-07-22 2017-07-18 Evidence Soluções Farmacêuticas Ltda Epp Stabilized topical composition and process of obtaining composition stable topic
US20120046264A1 (en) 2010-08-17 2012-02-23 Biosante Pharmaceuticals, Inc. Commercial scale production methods for transdermal hormone formulations
US20120101073A1 (en) 2010-10-22 2012-04-26 Galleon Pharmaceutical, Inc. Novel Method For Treating Breathing Disorders or Diseases
US20120295911A1 (en) 2010-11-29 2012-11-22 Galleon Pharmaceuticals, Inc. Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases
EP3178465A1 (en) 2010-12-06 2017-06-14 Follica, Inc. Methods for treating baldness and promoting hair growth
US20120328549A1 (en) 2011-01-24 2012-12-27 Anterios, Inc. Oil compositions
US20140031323A1 (en) 2011-02-15 2014-01-30 Ramiro M. Perez Transdermal hormone composition and combined static-cyclic delivery
US9085562B2 (en) 2011-03-03 2015-07-21 Vanderbilt University 6-alkyl-N-(pyridin-2-yl)-4-aryloxypicolinamide analogs as mGluR5 negative allosteric modulators and methods of making and using the same
WO2012127501A2 (en) 2011-03-11 2012-09-27 Sanzyme Limited Composition for improving endometrial thickness during ovarian stimulation
JP6152092B2 (ja) 2011-05-15 2017-06-28 エーセラス ファーマシューティカルズ コーポレーション 経鼻投与のための徐放テストステロン鼻腔内ゲル、方法および複数回用量プレフィルアプリケーターシステム
US9084797B2 (en) 2011-05-23 2015-07-21 Besins Healthcare Luxembourg Sarl Progesterone treatment for improving sleep quality
WO2012166909A1 (en) 2011-06-03 2012-12-06 Galleon Pharmaceuticals, Inc. Compositions and methods for treating breathing control disorders or diseases
US10561656B2 (en) 2011-06-10 2020-02-18 Intra-Cellular Therapies, Inc. Organic compounds
US9724324B2 (en) 2011-07-20 2017-08-08 Perrigo Israel Pharmaceuticals Ltd. Topical oily foam compositions
US8951996B2 (en) 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
KR101494594B1 (ko) 2011-08-30 2015-02-23 주식회사 종근당 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
AU2012332254B2 (en) 2011-11-04 2017-06-22 Agile Therapeutics, Inc. Dermal delivery compositions and methods
US20130122051A1 (en) 2011-11-15 2013-05-16 Pharmaceutics International, Inc. Methods of preparing progesterone pharmaceutical compositions
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
RS62297B1 (sr) 2011-11-23 2021-09-30 Therapeuticsmd Inc Prirodne kombinovane hormonske supstitucione formulacije i terapije
US9334538B2 (en) 2011-12-06 2016-05-10 Annabelle Rodriguez Oquendo Method for pre-screening and correlation of underlying SCARB1 gene variation to infertility in women and therapeutic use of progestational and other medications in treatment
US9282995B2 (en) 2011-12-22 2016-03-15 Previvo Genetics, Llc Recovery and processing of human embryos formed in vivo
AU2013211876B2 (en) * 2012-01-26 2017-02-09 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
EP2630952A1 (en) 2012-02-23 2013-08-28 Novagali Pharma S.A. Self-preserved oil dispersions comprising boric acid
US20130224268A1 (en) 2012-02-27 2013-08-29 Newgen Biopharma Corp. Topical delivery of hormonal and non hormonal nano formulations, methods of making and using the same
US20130225412A1 (en) 2012-02-28 2013-08-29 Soroush Sardari Lodriche Silicon nanocarrier for delivery of drug, pesticides and herbicides , and for waste water treatment
WO2013127727A1 (en) 2012-02-29 2013-09-06 B. Braun Melsungen Ag Hormone containing emulsion comprising krill phospholipids
EP2875359A4 (en) 2012-03-30 2015-08-19 Charles R Drew University Of Medicine And Science COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING METABOLISM SYNDROME DISEASES
US20150072438A1 (en) 2012-04-18 2015-03-12 Siemens Healthcare Diagnostic Inc. Compounds and methods for preparation of conjugate reagents
EP2846755A1 (en) 2012-05-09 2015-03-18 SiO2 Medical Products, Inc. Saccharide protective coating for pharmaceutical package
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
PL2861073T3 (pl) 2012-06-18 2021-09-27 Therapeuticsmd, Inc. Rozpuszczalna kapsułka estradiolu do wprowadzania do pochwy
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) * 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
WO2014009434A1 (en) 2012-07-11 2014-01-16 Sandoz Ag Self-microemulsifying drug delivery system of abiraterone or abiraterone acetate
WO2014012117A1 (en) 2012-07-13 2014-01-16 South Dakota State University Compositions and methods for localized drug delivery through mammary papillae
KR102097663B1 (ko) 2012-07-27 2020-04-06 글리아, 엘엘씨 눈 질병 및 질환을 위한 조성물 및 치료
WO2014018932A2 (en) 2012-07-27 2014-01-30 Bunt Antonius Martinus Gustave Effluz inhibitor compositions and methods of treatment using the same
WO2014052792A1 (en) 2012-09-28 2014-04-03 Sio2 Medical Products, Inc. Halogenated or parylene polymer coating
US20150297733A1 (en) 2012-11-14 2015-10-22 Trimel Biopharma Srl Controlled release topical testosterone formulations and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
KR101586789B1 (ko) 2012-12-28 2016-01-19 주식회사 종근당 양이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물

Also Published As

Publication number Publication date
US20160030449A1 (en) 2016-02-04
IL248984A0 (en) 2017-01-31
US10098894B2 (en) 2018-10-16
US20190070197A1 (en) 2019-03-07
MX2016013693A (es) 2017-10-31
JP2017523138A (ja) 2017-08-17
CA2951284A1 (en) 2016-02-04
BR112016029338A2 (pt) 2017-08-22
EP3174542A1 (en) 2017-06-07
AU2015296609A1 (en) 2016-12-22
WO2016018993A1 (en) 2016-02-04
EP3174542A4 (en) 2018-01-03
RU2016141135A (ru) 2018-08-28
RU2016141135A3 (enExample) 2019-05-07

Similar Documents

Publication Publication Date Title
US10098894B2 (en) Transdermal cream
US10912783B2 (en) Formulations for solubilizing hormones
US11123283B2 (en) Soluble estradiol capsule for vaginal insertion
JP5727494B2 (ja) 活性剤を含む経皮医薬組成物
CA2207144C (en) A novel composition for transdermal administration of an estrogen, a progestin or a mixture thereof
AU778889B2 (en) Novel topical oestroprogestational compositions with systemic effect
US20050152956A1 (en) Method of increasing testosterone and related steroid concentrations in women
US20190282698A1 (en) Steroid hormone compositions in medium chain oils
US20180280411A1 (en) Steroid hormone pharmaceutical composition
CN1809339B (zh) 用于出生后荷尔蒙替代品的油乳状液
KR20030048021A (ko) 여성의 테스토스테론 및 관련된 스테로이드의 농도를증가시키는 방법
DE60223795T2 (de) Tetrahydroxyliertes Östrogen enthaltendes Arzneistoffverabreichungssystem zur Verwendung in der hormonalen Kontrazeption
JP2010511730A (ja) テストステロンおよびプロゲスターゲンを用いたドライアイのための処置
AU2017208300A1 (en) Soluble Estradiol Capsule For Vaginal Insertion
KR20170005819A (ko) 천연 복합 호르몬 대체 제형 및 요법
WO2008089405A1 (en) Composition of multiple hormones delivered vaginally in a single cream
EP1660029A2 (en) Compositions containing topical active agents and pentylene glycol
ES2617334T3 (es) Parches transdérmicos de dosificación baja con liberación elevada de fármaco
PL214858B1 (pl) Środek leczniczy na bazie noretysteronu lub jego farmaceutycznie dopuszczalnej pochodnej i estradiolu lub jego farmaceutycznie dopuszczalnej pochodnej

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170125

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination